Patrick Trojer, PhD
Advisor

Patrick Trojer is an Advisor at Raven and President, Chief Executive Officer, and board member of TRIANA Biomedicines. He also chairs the board of Booster Therapeutics. Since joining TRIANA in November 2021, Patrick has led the company’s development of molecular glue medicines; its lead cancer program entered a Phase 1⁄2 clinical trial in 2026.

Previously, Patrick co-founded Constellation Pharmaceuticals and served as its Chief Scientific Officer. He helped build its drug discovery platform and advance a portfolio of clinical candidates, while contributing to the company’s financings, public offering, and eventual acquisition in 2021. He brings more than 15 years of drug discovery and oncology experience.

Patrick completed postdoctoral research in Dr. Danny Reinberg’s laboratory at NYU School of Medicine, studying how changes to histone modifications affect gene regulation. He earned a PhD in Biochemistry and Molecular Biology from the University of Innsbruck in Austria.

Department
Raven
Degree
PhD
University / College
Leopold-Franzens University, Innsbruck
Patrick Trojer